Skip to main content

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Active, not recruiting · Phase 3 · NCT04793958

Conditions: Advanced Colorectal Cancer, Metastatic Colorectal Cancer

At a glance

Research payments reported, 2025
$1.3M
U.S. investigators named
51
Sites paid
36
Planned or actual enrollment
461

About the trial

Sponsor
Mirati Therapeutics Inc.
Tested
MRTX849 (drug), Cetuximab (biological), mFOLFOX6 Regimen (drug), FOLFIRI Regimen (drug)
Dates
Started 2021-06-24; completion 2026-10-23
Results posted
Not yet

Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

From ClinicalTrials.gov, last updated 2026-09-28. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Mirati Therapeutics, Inc. reported $1.3M in research payments for this study in 2025 (76 payments).

Products named: Krazati

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • University of Washington Medical Ctr, WA $191,807
  • Memorial Sloan-Kettering Cancer Center - Cancer $166,254
  • Sarah Cannon Research Institute, Llc $156,593
  • Mayo Clinic Hospital, AZ $153,215
  • Inova Fairfax Hospital, VA $97,982
  • Translational Oncology Research International $62,093
  • Cedars-Sinai Medical Center, CA $48,913
  • Ut MD Anderson Cancer Center $47,420
  • Edward Elmhurst Health $44,731
  • Board of Regents of the University of Oklahoma Health Sciences Center $39,695
  • Us Oncology Res Llc $37,113
  • Saint Joseph Health System $33,410
  • Usc Norris Cancer Hospital $28,553
  • Mayo Clinic Jacksonville $22,905
  • Fundacion De Investigacion $21,181
  • UCSF Langley Porter Psychiatric Hospital and Clinics, CA $19,383
  • Utah Cancer Specialists $18,781
  • St. Francis Hospital & Health Center $18,200
  • Oncare Alliance, Llc $17,937
  • Sloan Kettering Institute for Cancer Research $17,007
  • Dallas VA Research Corporation $14,800
  • NYU Langone Hospitals - Tisch Hospitals Clinical Labs $14,218
  • Ocala Oncology Center, Pl $13,929
  • Titan Health PArtners Llc $13,558
  • University of Iowa Hospital & Clinics, IA $12,460
  • Adventhealth Orlando, FL $8,513
  • Birmingham Hematology and Oncology Ass,llc $5,958
  • Southeastern Medical Oncology Center $5,212
  • Dana-Farber Cancer Institute $4,500
  • Hematology / Oncology Associates of Fredricksburg, Incorporated $3,475
  • Highland Oncology Group $2,203
  • Cleveland Clinic Florida Aetna Aco $2,025
  • Pan American Center for Oncology Trials Llc $1,887
  • Millennium Research & Clinical Development $1,477
  • Healthpartners Institute for Education and Research $680
  • Oncology Consultants, PA $328

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.